AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oramed Pharmaceuticals Inc. Director's Dealing 2025

Jan 6, 2025

6965_dirs_2025-01-06_dbe964d8-61ca-4b46-80b2-07ffe1d7eef3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORAMED PHARMACEUTICALS INC. (ORMP)
CIK: 0001176309
Period of Report: 2025-01-02

Reporting Person: KIDRON NADAV (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-01-02	Common Stock	A	433500	—	Acquired	2259598	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	126000	Indirect

Footnotes

F1: Represents Restricted Stock Units ("RSUs") that will vest in quarterly installments of approximately 36,125 over a three year period starting January 1, 2025. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.